Far Infrared Treatment for Alzheimer's Disease

Alzheimer Disease Clinical Trial

Official title:

Phase 1 Study to Determine the Efficacy of Using Far Infrared Radiation for the Treatment of Alzheimer's Disease.

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT00599469
• Other study ID #: GAAD-AD-CTP1
• Status: Active, not recruiting
• Phase: Phase 1
• First received: January 11, 2008
• Last updated: August 14, 2009
• Start date: February 2008
• Est. completion date: April 2009

Study information

• Verified date: August 2009
• Source: GAAD Medical Research Institute Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Interventional

Clinical Trial Summary

Alzheimer's disease is a progressive and fatal brain disease. This study will investigate the use of far infrared radiation treatment for the disease.

Description:

Alzheimer's destroys brain cells, causing problems with memory, thinking and behaviour severe enough to affect work, lifelong hobbies or social life. Alzheimer's gets worse over time and it is fatal.

Alzheimer's, which has no current cure, is the most common form of dementia. It is hereby postulated that far infrared radiation of the central nervous and endocrine systems will help with the management of the disease and possibly cure the disease.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 4
• Est. completion date: April 2009
• Est. primary completion date: March 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• People with Alzheimer's disease

Exclusion Criteria:

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Alzheimer Disease

Intervention

Radiation:
• Far Infrared Radiation (5µm to 20µm wavelength)
Far Infrared radiation for 30 to 40 minutes per treatment session.

Locations

Country	Name	City	State
Canada	The Centre for Incurable Diseases	Toronto	Ontario

Sponsors (1)

Lead Sponsor	Collaborator
GAAD Medical Research Institute Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Management and Cure of Alzheimer's Disease		1 year	No
Secondary	Management and Cure of Dementia		1 year	No